Browsing by Author Kefford, Richard (Rick)

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 21 to 40 of 146 < previous   next >
Issue DateTitleAuthor(s)Citation
2015Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase 1/2 clinical trialKefford, Richard (Rick); Long, Georgina; Menzies, Alexander Maxwel; Ashworth, Michelle T; et al, Various; Flaherty, Keith; Gonzalez, Rene; Hamid, Omid; Infante, Jeffrey; Kim, K B; Schuchter, Lynn; Swann, S; Weber, Jeffrey; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: MedicineCharacteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase 1/2 clinical trial, Annals of Oncology, vol.26, 2, 2015,pp 415-421
2005Chemotherapeutic induced fascial oedemaKefford, Richard (Rick); Manolios, Nicholas; Lim, I.G.S.; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead)Chemotherapeutic induced fascial oedema, Annals of the rheumatic diseases, vol.64,(1),2005,pp 162-163
2009The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4aBecker, Therese; Diefenbach, Eve; Dijkstra, Menno; Frausto, Monika; Haferkamp, Sebastian; Kefford, Richard (Rick); Mann, Graham; Rizos, Helen; Scolyer, Richard; Scurr, Lyndee; Reisman, David N.; Western Clinical School: Westmead Millennium Institute; Sydnovate; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Western Clinical School (Westmead): Office; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Central Clinical School: Pathology; Western Clinical School: Medicine (Westmead)The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a, Molecular Cancer, vol.8,(4),2009,pp 4-1-4-12
2009Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa TrialKefford, Richard (Rick); Brady, Ben; Cebon, Jonathon; Davis, Ian; Hansen, Lasse T.; Lundsgaard, Dorthe; Millward, Michael; Mouritzen, Ulrik; Skak, Kresten; Skrumsager, Birte K.; Western Clinical School: Westmead Millennium InstituteClinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial, Clinical Cancer Research, vol.15, 6,pp 2123-2129
2012Clinical and Pathologic Factors Associated with Distant Metastasis and Survival in Patients with Thin Primary Cutaneous MelanomaHaydu, Lauren; Kefford, Richard (Rick); Long, Georgina; Murali, Rajmohan; Quinn, Michael; Saw, Robyn; Scolyer, Richard; Shannon, Kerwin; Spillane, Andrew; Stretch, Jonathan; Thompson, John; Central Clinical School: Surgery; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: Pathology; School of Public Health: NH&MRC Clinical Trials Centre; Central Clinical School: Surgery; Central Clinical School: Pathology; Medicine; Northern Clinical School: Medicine; Central Clinical School: Surgery; Central Clinical School: SurgeryClinical and Pathologic Factors Associated with Distant Metastasis and Survival in Patients with Thin Primary Cutaneous Melanoma, Annals of Surgical Oncology, vol.19, 6, 2012,pp 1782-1789
2017Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicingCarlino, Matteo; Kefford, Richard (Rick); Long, Georgina; Menzies, Alexander Maxwel; Pedersen, Bernadette; Pupo, Gulietta; Rizos, Helen; Scolyer, Richard; Boyd, Suzanah C; Fung, Carina; Hayward, Nicholas K; Johansson, Peter; Westmead Clinical School: Medicine; Westmead Clinical School: Medicine; Northern Clinical School: Medicine; Northern Clinical School: Medicine; Westmead Clinical School: Westmead Institute for Medical Res; Westmead Clinical School: Medicine; Westmead Clinical School: Westmead Institute for Medical Res; Central Clinical School: PathologyClinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing, Biomarker Research, vol.5, 17, 2017,pp 1-4
2015Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitorsCarlino, Matteo; Drummond, Martin John; Guminski, Alexander; Kefford, Richard (Rick); Lo, Serigne; Long, Georgina; Lyle, Megan; Menzies, Alexander Maxwel; Scolyer, Richard; Thompson, John; Wilmott, James; Chan, Matthew M K; Western Clinical School: Medicine (Westmead); School of Public Health: Public Health; Medicine Faculty Office; Western Clinical School: Westmead Institute for Medical Res; The George Institute for Global Health; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: Melonoma & Skin Cancer Res. Inst.; Central Clinical School: Medicine; Central Clinical School: Pathology; Central Clinical School: Surgery; Central Clinical School: SurgeryClinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors, Cancer, vol.121, 21, 2015,pp 3826-3835
2014Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitorKefford, Richard (Rick); Long, Georgina; Cebon, Jonathan Simon; et al, Various; Flaherty, Keith; Hamid, Omid; Infante, Jeffrey; Johnson, Douglas B; Kim, Kevin; McWilliams, Robert; Schuchter, Lynn; Sharfman, William; Weber, Jeffrey; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentreCombined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor, Journal of Clinical Oncology, vol.32, 33, 2014,pp 3697-3704
2008Common sequence variants on 20q11.22 confer melanoma susceptibilityArmstrong, Bruce; Holland, Elizabeth; Kefford, Richard (Rick); Mann, Graham; Schmid, Helen; Brown, Kevin M; Campbell, M; Craig, David W; et al, Various; Henders, Anjali; Homer, Nils; Iyadurai, Kelly; MacGregor, Stuart; Montgomery, Grant W.; Stark, Mitchell; Thomas, Shane; Zhao, Zhen Zhen; School of Public Health: Public Health; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead)Common sequence variants on 20q11.22 confer melanoma susceptibility, Nature Genetics, vol.40, 7, 2008,pp 838-840
2014Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomasKakavand, Hojabr; Kefford, Richard (Rick); Long, Georgina; O'Toole, Sandra; Scolyer, Richard; Thompson, John; Wilmott, James; Crainic, Oana; Lum, Trina; Central Clinical School: Melonoma & Skin Cancer Res. Inst.; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: Pathology; Central Clinical School: Pathology; Central Clinical School: Surgery; Central Clinical School: SurgeryConcordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas, Pathology, vol.46, 3, 2014,pp 193-198
2014Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanomaCarlino, Matteo; Hamilton, Anne; Haydu, Lauren; Kakavand, Hojabr; Kefford, Richard (Rick); Long, Georgina; Menzies, Alexander Maxwel; O'Toole, Sandra; Scolyer, Richard; Thompson, John; Yu, Bing; Cooper, Wendy; Ng, C; Western Clinical School: Medicine (Westmead); Central Clinical School: Medicine; Central Clinical School: Surgery; Central Clinical School: Melonoma & Skin Cancer Res. Inst.; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: Medicine; Central Clinical School: Pathology; Central Clinical School: Pathology; Central Clinical School: Surgery; Central Clinical School: MedicineCorrelation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma, British Journal of Cancer, vol.111, 2, 2014,pp 292-299
2016Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trialsKefford, Richard (Rick); Long, Georgina; Carver, Jennifer; Casey, Michelle; Flaherty, Keith; Gagnon, Robert; Goodman, Vicki; Haney, Patricia; Hauschild, Axel; Hwu, Patrick; Legos, Jeffrey J.; Martin, Anne-Marie; Mazumdar, Jolly; O'Hagan, Anne; Santiago-Walker, Ademi; Schadendorf, D; Western Clinical School: Westmead Institute for Medical Res; Central Clinical School: The Sydney Cancer CentreCorrelation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials, Clinical Cancer Research, vol.22, 3, 2016,pp 567-574
2015Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeksAnforth, Rachael; Carlos, Giuliana R M; Clements, Arthur; Fernandez Penas, Pablo; Kefford, Richard (Rick); Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium InstituteCutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks, British Journal of Dermatology, vol.172, 1, 2015,pp 239-243
2012Cutaneous Manifestations of Dabrafenib (GSK2118436): A Selective Inhibitor of Mutant BRAF in patients with Metastatic MelanomaAnforth, Rachael; Fernandez-Penas, Pablo; Kefford, Richard (Rick); Long, Georgina; Scolyer, Richard; Blumetti, Tatiana Cristina Moraes Pinto; Kossard, Steven; Sharma, Raghwa; Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: PathologyCutaneous Manifestations of Dabrafenib (GSK2118436): A Selective Inhibitor of Mutant BRAF in patients with Metastatic Melanoma, British Journal of Dermatology, vol.167, 5, 2012,pp 1153-1160
2005Cutaneous melanoma.Kefford, Richard (Rick); Scolyer, Richard; Thompson, John; Western Clinical School: Westmead Millennium Institute; Central Clinical School: Pathology; Central Clinical School: SurgeryCutaneous melanoma., The Lancet, vol.365,(9460),2005,pp 687-701
2007Cutaneous melanoma/Authors' replyKefford, Richard (Rick); Menzies, Scott; Shaw, Helen; Thompson, John; Western Clinical School: Westmead Millennium Institute; Central Clinical School: Medicine; Central Clinical School: Sydney Melanoma Unit; Central Clinical School: SurgeryCutaneous melanoma/Authors' reply, The Lancet, vol.365,(9476),2007,pp 2004-2005
2012Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trialKefford, Richard (Rick); Long, Georgina; Arkenau, Tobias; Brown, Michael P.; et al, various; Falchook, GErald; Hamid, Omid; Infante, Jeffrey; Kim, Kevin; Kurzrock, Razelle; Millward, Michael; O'Day, Steven; Pavlick, Anna C.; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentreDabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial, The Lancet, vol.379, 9829, 2012,pp 1893-1901
2012Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trialKefford, Richard (Rick); Long, Georgina; Algazi, Alain; Ascierto, Paolo; Chapman, Paul; Davies, Michael; et al, Various; Hauschild, A; Mortier, Laurent; Puzanov, Igor; Robert, C; Tawbi, Hussein; Trefzer, Uwe; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentreDabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial, The Lancet Oncology, vol.13, 11, 2012,pp 1087-1095
2004Deletion Mapping Suggests That The 1P22 Melanoma Susceptibility Gene Is A Tumor Suppressor Localized To A 9-Mb Interval.Kefford, Richard (Rick); Mann, Graham; Brown, Kerry; Duray, Paul; Faruque, Mezbah; Hayward, Nicholas; Holland, Elizabeth A.; Hu, Ping; Indsto, James O.; Pollock, Pam M.; Sood, Raman; Trent, Jeffrey; Walker, Graeme J.; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium InstituteDeletion Mapping Suggests That The 1P22 Melanoma Susceptibility Gene Is A Tumor Suppressor Localized To A 9-Mb Interval., Genes Chromosomes and Cancer, vol.41,(1),2004,pp 56-64
2014Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanomaCarlino, Matteo; Fung, C.; Gowrishankar, Kavitha; Hersey, Peter; Kefford, Richard (Rick); Long, Georgina; Mijatov, Branka; Pupo, Gulietta; Rizos, Helen; Snoyman, Stephanie; Todd, Jason; Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Northern Clinical School: Surgery; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium InstituteDifferential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma, Molecular Oncology, vol.8, 3, 2014,pp 544-554